Want to see MRVI full AI Analyst Report?
Adjusted EBITDA by Segment
Shows profitability across different business units, highlighting which segments are driving earnings and where there might be opportunities or challenges in cost management.Nucleic Acid Production collapsed from pandemic-era peaks into low or negative adjusted EBITDA as CleanCap tailwinds faded, leaving TriLink dependent on new products and cost cuts to recover. Biologics Safety Testing is a steady, high‑margin cash engine (Cygnus) that underpins profitability and debt reduction. Management’s exceeded cost‑savings and 2026 guidance support cautious optimism for a full‑year EBITDA turnaround, but order lumpiness, leverage and prior impairments keep execution risk elevated.
Date | Nucleic Acid Production | Biologics Safety Testing |
|---|---|---|
Jun 30, 2026 | $7.03M | $11.38M |
Mar 31, 2026 | $17.26M | $13.56M |
Dec 31, 2025 | $936.00K | $10.17M |
Sep 30, 2025 | -$7.92M | $10.54M |
Jun 30, 2025 | -$7.27M | $10.86M |
Mar 31, 2025 | -$8.90M | $12.67M |
Dec 31, 2024 | $3.97M | $9.54M |
Sep 30, 2024 | $15.46M | $10.93M |
Jun 30, 2024 | $21.30M | $9.45M |
Mar 31, 2024 | $10.09M | $13.93M |